erythromycin + azithromycin + clarithromycin

This entry refers to a clinical research protocol involving the macrolide antibiotics erythromycin, azithromycin, and clarithromycin, specifically as investigated by Baqiyatallah Medical Sciences University for the management of difficult asthma and chronic bronchiolitis. These small molecule agents are traditionally used for their antibacterial properties, which involve binding to the 50S ribosomal subunit to inhibit protein synthesis. However, in the context of chronic airway diseases, they are valued for their secondary immunomodulatory effects, including the inhibition of NF-kB signaling and the reduction of pro-inflammatory cytokines like IL-8. The Phase 4 trial aims to utilize the clinical response to these macrolides as both a diagnostic tool and a therapeutic intervention to distinguish between steroid-resistant asthma and chronic bronchiolitis, a condition frequently observed in Iranian veterans exposed to sulfur mustard gas.

Other names

Macrolides for Difficult Asthma or Chronic Bronchiolitis